Assessing the Efficacy of Maxidex® and Patanol® for the Treatment of Allergic Conjunctivitis

Completed · Phase 4 · Has a placebo group

Conditions studied: Allergic Conjunctivitis

In brief

The purpose of this study was to evaluate the efficacy of Maxidex and Patanol compared to placebo in patients with allergic conjunctivitis when exposed to controlled allergen levels in an Environmental Exposure Chamber (EEC).

Key facts

Study ID

NCT01119287

Run by

Alcon Research

People needed

180

Starts

2010-03-01

Expected to finish

2010-09-01

Last updated by the study team

2014-02-28

Who can join

Age: 18 and older, up to 64. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 1 year history of allergic conjunctivitis.
• Ability to self administer ophthalmic drops.
• Ability to avoid use of disallowed medications during the entire study period and specified period prior to visit 1.
• Other protocol-specified inclusion criteria may apply.

You may not qualify if…

• Presence of any ocular infection.
• Confirmed diagnosis of dry eye.
• Presence of glaucoma or ocular hypertension.
• Moderate to severe asthma.
• Any severe, unstable, or uncontrolled systemic disease.
• Other protocol-defined exclusion criteria may apply.

Where it is running

• Contact Alcon Call Center For Trial Locations — Fort Worth, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.